Bantam Pharmaceutical
Bantam Pharmaceutical is a drug discovery and development company focused on addressing unmet needs in oncology by channeling the power of mitochondrial dynamics. They develop novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors, with a lead candidate BTM-3566 targeting mitochondrial homeostasis to induce cancer cell apoptosis. The company aims to revolutionize cancer treatment through pioneering science and expertise in mitochondrial cellular biology, seeking partners and investors to accelerate clinical research and bring therapies closer to patients.
Industries
Nr. of Employees
small (1-50)
Bantam Pharmaceutical
Boston, Massachusetts, United States, North America
Products
Lead oral small-molecule clinical candidate (mitochondrial dynamics modulator)
A lead orally administered small-molecule clinical candidate that pharmacologically activates a mitochondrial protease and the integrated stress response to induce apoptosis in tumor cells; developed for B‑cell hematological malignancies with evidence of broad preclinical activity.
Lead oral small-molecule clinical candidate (mitochondrial dynamics modulator)
A lead orally administered small-molecule clinical candidate that pharmacologically activates a mitochondrial protease and the integrated stress response to induce apoptosis in tumor cells; developed for B‑cell hematological malignancies with evidence of broad preclinical activity.
Services
Collaborative drug discovery and development partnerships
Partnering with academic groups and external collaborators to advance preclinical research, validate mechanism of action, and support translational studies toward clinical development.
Early-phase clinical development and site activation
Management and operational support to initiate first‑in‑human and Phase 1 oncology studies, including clinical site activation and trial expansion.
Collaborative drug discovery and development partnerships
Partnering with academic groups and external collaborators to advance preclinical research, validate mechanism of action, and support translational studies toward clinical development.
Early-phase clinical development and site activation
Management and operational support to initiate first‑in‑human and Phase 1 oncology studies, including clinical site activation and trial expansion.
Expertise Areas
- Oncology drug discovery and preclinical development
- Mitochondrial biology and modulation of mitochondrial dynamics
- Preclinical pharmacology and in vivo tumor modeling (xenograft and PDX)
- Biomarker discovery and precision medicine
Key Technologies
- Phenotypic screening (protein translational screens, high-content assays)
- Patient-derived xenograft (PDX) models
- In vivo xenograft efficacy models
- Small-molecule oral therapeutic development